Santos et al., Blood 2010
(Polycythemia Vera...) :
Phase 2 study of CEP-701 , an orally available JAK2 inhibitor , in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Stump et al., Arthritis Res Ther 2011
(Arthritis, Experimental...) :
In this paper, we describe the efficacy profile of CEP-33779 , a highly selective, orally active, small-molecule inhibitor of JAK2 evaluated in two mouse models of RA